In untreated relapsing-remitting MS (RRMS), a similar level of EBI2 expression was found in patients and the healthy controls; however, there was significant variability in EBI2 receptor levels found in CD4+ and CD1 T cells in the MS patients’ samples [18]. Here, GPR183 is linked to myeloid sarcoma.